Inactive Instrument

Press Releases Coronado Biosciences Inc Nasdaq

Equities

US21976U1097

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Fortress Biotech : Private Placement Form 8 K	06-28	PU
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	05-16	AQ
Fortress Biotech: Q1 Earnings Snapshot	05-15	AQ
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	05-15	AQ
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	05-15	AQ
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	05-14	AQ
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	05-13	AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	05-07	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	05-01	AQ
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	04-29	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	04-25	AQ
Avenue Therapeutics Announces Reverse Stock Split	04-24	AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	03-28	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	03-26	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	03-21	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	03-18	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	03-15	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	03-13	AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference	03-12	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	03-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Coronado Biosciences Inc Nasdaq

Equities

US21976U1097

Press Releases

Filters